Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track UPB with free AI briefings, catalyst countdowns, and dilution alerts.

UPB · Upstream Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$207.4M Cash on Hand
13.8mo Cash Runway
Follow UPB by email Get an email when UPB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about UPB, unsubscribe in one click. Privacy

📣 What UPB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Verekitug Severe Asthma Phase 2 · NCT06966479 Active not recruiting
UPB-101 Asthma Phase 1 · NCT05448651 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

UPB holds $207.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $44.9M/quarter from operations, an estimated runway of 13.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 38 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when UPB files for a raise →

👥 Who Owns UPB

Insiders 8.6% Institutions (201 holders) 91.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Erez Chimovits
Director · +34,192 options
Insider 4,554,873 8.31% 2024-10-15
Norges Bank Institution (13G, 5%+) 4,206,586 7.67% 2026-06-30
FMR LLC Institution (13G, 5%+) 3,793,955 6.92% 2026-10-30
BlackRock, Inc. Institution (13G, 5%+) 2,814,714 5.14% 2026-06-30
Everett Rand Sutherland
Chief Executive Officer, Director · +725,000 options
Insider 68,717 0.13% 2026-09-16
Aaron Deykin
Chief Medical Officer · +261,000 options
Insider 32,302 0.06% 2026-09-16
Michael Gray
CFO and COO · +286,500 options
Insider 27,942 0.05% 2026-09-16
Adam Houghton
Chief Business Officer · +215,000 options
Insider 22,901 0.04% 2026-09-16
Allison Ambrose
General Counsel · +176,000 options
Insider 15,563 0.03% 2026-09-16

Share count 54,811,391 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full UPB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UPB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.